Francois Nader Insider Trading $XLRN ACCELERON PHARMA INC
Get free email notifications about insider trading for Francois Nader.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Francois Nader. Francois Nader is Chief Medical & Commercial Off in NPS PHARMACEUTICALS INC ($NPSP) and Chief Operating Officer in NPS PHARMACEUTICALS INC ($NPSP) and President, CEO and Director in NPS PHARMACEUTICALS INC ($NPSP) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and Director in ACCELERON PHARMA INC ($XLRN) and Director in TREVENA INC ($TRVN) and Director in Baxalta Inc ($BXLT) and Director in Moderna, Inc. ($MRNA) and Director in Prevail Therapeutics Inc. ($PRVL).
Francois Nader in ACCELERON PHARMA INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Francois Nader: Director
Holdings: 5,127 shares
Current Value: $121,715
Latest Transaction: Jan 24 2020
$XLRN Market Capitalization: $879.48M
$XLRN Previous Close: $23.74
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Francois Nader in ACCELERON PHARMA INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, XLRN, ALXN, BXLT, MRNA, NPSP, PRVL, TRVN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
| Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,377 | 0 | 5,127 | 3.8 K to 5.1 K (+36.72 %) |
| Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 41.64 | 7,500 | 312,300 | 7,500 | |
| Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 3,750 | 2.5 K to 3.8 K (+50.00 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 2,500 | 1.3 K to 2.5 K (+100.00 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 27.97 | 10,000 | 279,700 | 10,000 | |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 34.14 | 10,000 | 341,400 | 10,000 |
Page: 1